Aster DM Healthcare Limited

100%

oard of directors of Aster DM Healthcare (“Company” or “Aster”) at their meeting today approved the 100% sale of its GCC business (“GCC Business”) ▪ GCC Business will be acquired by Alpha GCC Holdings Li

INR13,540

ubai International Financial Centre (“Aster GCC”) at an Enterprise Value of US$1,651.2m (equal to INR13,540cr) ▪ At the closing of the Transaction, Fajr Capital & its consortium members will own ~65% and a

65%

INR13,540cr) ▪ At the closing of the Transaction, Fajr Capital & its consortium members will own ~65% and a Promoter entity1 will own the remaining ~35% stake in the GCC Business through Aster GCC T

35%

Fajr Capital & its consortium members will own ~65% and a Promoter entity1 will own the remaining ~35% stake in the GCC Business through Aster GCC Transaction Overview ▪ Aster shareholders will con

INR10,666

Transaction Details (GCC Business) ▪ Equity Value ▪ EBITDA4 FY23 Pre- Ind AS 116 US$1,300.7m (INR10,666cr) US$1,001.8m (INR8,215cr) Post- Ind AS 116 US$ 1,651.2m (INR13,540cr) US$ 1,001.8m (INR 8,215

INR8,215

Business) ▪ Equity Value ▪ EBITDA4 FY23 Pre- Ind AS 116 US$1,300.7m (INR10,666cr) US$1,001.8m (INR8,215cr) Post- Ind AS 116 US$ 1,651.2m (INR13,540cr) US$ 1,001.8m (INR 8,215cr) Upfront consideration

INR 8,215

INR10,666cr) US$1,001.8m (INR8,215cr) Post- Ind AS 116 US$ 1,651.2m (INR13,540cr) US$ 1,001.8m (INR 8,215cr) Upfront consideration of US$ 903m5 and up to US$98.8m to be received subsequently6 Upfront co

INR 751 Crore

y6 Upfront consideration of US$ 903m5 and up to US$98.8m to be received subsequently6 US$ 91.6m (INR 751 Crores) US$ 138.9m (INR 1,139 Crores) ▪ Multiple EV / EBITDA FY23 14.2x 11.9x ▪ Finalization of defi

INR 1,139 Crore

US$ 903m5 and up to US$98.8m to be received subsequently6 US$ 91.6m (INR 751 Crores) US$ 138.9m (INR 1,139 Crores) ▪ Multiple EV / EBITDA FY23 14.2x 11.9x ▪ Finalization of definitive financing documents ▪ S

14.2x

sequently6 US$ 91.6m (INR 751 Crores) US$ 138.9m (INR 1,139 Crores) ▪ Multiple EV / EBITDA FY23 14.2x 11.9x ▪ Finalization of definitive financing documents ▪ Shareholder’s approval ▪ Completion of

11.9x

ly6 US$ 91.6m (INR 751 Crores) US$ 138.9m (INR 1,139 Crores) ▪ Multiple EV / EBITDA FY23 14.2x 11.9x ▪ Finalization of definitive financing documents ▪ Shareholder’s approval ▪ Completion of certai

INR 82

ected to occur by Q4 FY247 Key Pending Approvals & Items Target Completion Date Note: 1USD = INR 82 FX rate has been used for all conversion (1) “Promoter entity” refers to Dr. Moopen Family Holding C

Note

1

Investor Relations

1

Note

(1) Clinics include Diagnostics ; Pharmacies include optics (2) Pharmacies in India are operated by ARPPL under brand license from Aster DM 11 Post-Segregation Structure INDIA LISTED ENTITY GCC ENTITY Promoters 41.88% Public 58.12% Promoters 35% Fajr Consortium 65% Aster DM Healthcare Limited Aster GCC3 Hospitals Clinics Pharmacies1 Labs & PECs Hospitals Clinics2 Pharmacies2 Kerala Karnataka Maharashtra Telangana Andhra Pradesh UAE KSA Oman Qatar Bahrain Jordan ▪ ▪ ▪ No change in shareholding in India listed entity due to segregation Promoters to maintain their ~42% stake in the India listed entity and will hold 35% stake in the GCC entity Details of Aster Shareholders and the buyer group on the following slides Pharmacies in India are operated by ARPPL under brand license from Aster DM (1) (2) Clinics include Diagnostics ; Pharmacies include optics (3) Held by an entity named Alpha GCC Holdings Limited 12 Shareholders of the India listed entity Marquee domestic and foreign institution